Teladoc Health Inc. (TDOC) saw its stock price soar 5.06% during intraday trading on Friday, following the release of its first-quarter 2026 financial results.

The company reported a narrowing net loss on a trailing 12-month basis, from US$200.3 million in Q4 2025 to US$171.1 million in Q1 2026, with basic EPS loss improving from US$1.14 to US$0.96 over the same period. This loss reduction reinforces the bullish narrative that Teladoc is moving toward better margins, despite revenue growth remaining modest at 1.7% annually.

Investors reacted positively to these improving financial metrics, as the company continues to focus on tightening margins and shrinking losses. The stock's movement reflects optimism about Teladoc's path to profitability, even as revenue trends remain relatively flat.